Richard Creager

Dr. Creager has more than 35 years of experience in the in vitro diagnostics (IVD) industry. During his career, he led the development and commercialization of more than 160 IVD products for infectious disease, cardiovascular disease, fertility, thyroid disease, autoimmune disease, cancer, and women’s health.

Currently, Dr. Creager is the founder of NaviDx LLC, a management consultant firm for IVD and biotechnology companies. He is a business consultant for the SBDC @UCI Beall Applied Innovation and an advisor to the National Institutes of Health (NIH) RADx, a fast-track program that supports the development and commercialization of innovative technologies to significantly increase the U.S. testing capacity for SARS-CoV-2, the virus that causes COVID-19.

Previously, Dr. Creager was the SVP Molecular Diagnostics and Chief Science Officer for Beckman Coulter. He served as Group Vice President for Beckman Coulter’s Immunoassay Business and held senior executive positions with Kallestad Diagnostics and Sanofi Diagnostics Pasteur. In addition, Dr. Creager served as chairman of the board for Medical Alley, a 501(c)3 non-profit trade association of healthcare companies in Minnesota. He currently serves on the board of directors for the 1for2 education foundation, OnRamp Bioinformatics, and Seraph Biosciences.

Dr. Creager has a B.S. from Muhlenberg College, a M.S. from Duquesne University, and a Ph.D. from the University of Pittsburgh School of Medicine. He also attended The Wharton School of Business for Advanced Management Program.